Analysts at Oppenheimer initiated coverage on shares of Benitec Biopharma (NASDAQ:BNTC - Get Free Report) in a report released on Wednesday, MarketBeat reports. The firm set an "outperform" rating and a $35.00 price target on the biotechnology company's stock. Oppenheimer's target price would indicate a potential upside of 256.78% from the company's current price.
A number of other research analysts have also issued reports on the company. Leerink Partnrs raised Benitec Biopharma to a "strong-buy" rating in a report on Monday, July 22nd. Leerink Partners started coverage on Benitec Biopharma in a report on Monday, July 22nd. They issued an "outperform" rating and a $13.00 target price on the stock. Guggenheim started coverage on Benitec Biopharma in a report on Thursday, September 12th. They issued a "buy" rating and a $17.00 target price on the stock. Finally, JMP Securities boosted their target price on Benitec Biopharma from $16.00 to $18.00 and gave the company a "market outperform" rating in a report on Monday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $22.60.
Get Our Latest Report on Benitec Biopharma
Benitec Biopharma Stock Performance
NASDAQ BNTC remained flat at $9.81 on Wednesday. The company's stock had a trading volume of 34,190 shares, compared to its average volume of 46,716. Benitec Biopharma has a one year low of $2.69 and a one year high of $12.89. The company's 50-day moving average is $9.11 and its 200-day moving average is $8.32. The firm has a market capitalization of $91.90 million, a PE ratio of -5.45 and a beta of 0.90.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in Benitec Biopharma by 20.3% during the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 1,102 shares during the period. Simplify Asset Management Inc. acquired a new position in Benitec Biopharma during the second quarter worth $358,000. Janus Henderson Group PLC grew its holdings in Benitec Biopharma by 35.5% during the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company's stock worth $1,266,000 after acquiring an additional 64,092 shares during the period. Finally, Nantahala Capital Management LLC acquired a new stake in Benitec Biopharma in the second quarter valued at $5,881,000. Institutional investors and hedge funds own 52.19% of the company's stock.
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
See Also
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
